Premium
Incorporating ruthenium into advanced drug delivery carriers – an innovative generation of chemotherapeutics
Author(s) -
Blunden Bianca M.,
Stenzel Martina H.
Publication year - 2015
Publication title -
journal of chemical technology and biotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.64
H-Index - 117
eISSN - 1097-4660
pISSN - 0268-2575
DOI - 10.1002/jctb.4507
Subject(s) - ruthenium , macromolecule , drug delivery , combinatorial chemistry , anticancer drug , nanotechnology , chemistry , liposome , targeted drug delivery , micelle , drug , materials science , organic chemistry , pharmacology , biochemistry , medicine , catalysis , aqueous solution
Ruthenium complexes have been shown to possess remarkable chemotherapeutic – both anticancer and antimetastatic – properties. Ruthenium possesses unique attributes that have led to the development of promising anticancer and antimetastatic therapeutics, for example, RAPTA‐C, KP1019 and NAMI‐A. The amplified benefit that can be gained by incorporating drugs into macromolecules has only recently been investigated for ruthenium agents. The advances in macromolecular chemistries has allowed for the incorporation and examination of some of these promising moieties within macromolecular matrices. Several nano‐sized delivery systems have also been developed for cancer treatment, for example, micelles, liposomes, peptide structures and hybrid moieties. The main findings of this novel body of work are presented here, highlighting the scope for further investigations. © 2014 Society of Chemical Industry